Abstract:Abstract Cyclin-dependent protein kinases (CDKs) regulate the eukaryotic cell cycle progression. Dysregulated cell cycle leading to unscheduled cell proliferation is a characteristic of many cancer subtypes. Since some tumor cells require specific interphase CDKs for proliferation, understanding CDKs activation mechanisms and their differential recognition of cognate cyclins and substrate proteins are essential for developing selective CDK inhibitors for cancer treatments. To date, while the crystal structure of the active CDK2 in complex with cyclin-E is available, no crystal structure for active CDK4 with its cognate cyclin-D is resolved. Here, we model the CDK4/cyclin-D complex as well as CDK2 in complex with cyclin-E to study the conformational dynamics and activation processes of G1 and G1/S phases CDKs, respectively. Extensive molecular dynamics (MD) simulations were performed for both CDK complexes with the kinases in different transition states to resolve the differences in their allosteric regulations at the atomic level. We illustrate that the inactive CDK4 in complex with cyclin-D is in the intermediate state on its pathway to activation in contrast to the fully active CDK2 in complex with cyclin-E, suggesting its activation mechanism is distinct from that of CDK2. This suggests that additional steps such as ATP binding, extension of the activation loop (A-loop), rotation of αC-helix towards “IN” conformation, phosphorylation of A-loop, and substrate binding are required for CDK4. CDK2 interacts with cyclin-E through a large interfacial area (or interface) that stabilizes the protein-protein interaction, while CDK4 has a smaller interfacial area (or interface) in the interaction with cyclin-D. Our simulations affirm experimental data on the current understanding of activation mechanisms of CDK2 and CDK4 and reveal additional atomistical characteristics of their dynamics and activations. Our works report the complete activation mechanisms of CDK2/4, providing insights into the inhibition of these complexes at an atomic level, and are useful for identifying potential targets for drug discovery in oncology. Citation Format: Wengang Zhang, Yonglan Liu, Mingzhen Zhang, Hyunbum Jang, Ruth Nussinov. Deciphering the activation mechanism of CDK4/cyclin-D complex that differs from the CDK2/cyclin-E complex [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 872.

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

New functional activities for the p21 family of CDK inhibitors.

Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F

Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1

CDK Inhibitors: Cell Cycle Regulators and Beyond

A cell cycle-regulated inhibitor of cyclin-dependent kinases.

Functional Collaboration Between Different Cyclin-Dependent Kinase Inhibitors Suppresses Tumor Growth with Distinct Tissue Specificity

Slower CDK4 and faster CDK2 activation in the cell cycle

Cell-cycle inhibitors: three families united by a common cause

The double dealing of cyclin D1

Cell Cycle Progression Mechanisms: Slower Cyclin-D/cdk4 Activation and Faster Cyclin-E/cdk2.

Cell cycle, CDKs and cancer: a changing paradigm

Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation

Inhibition of Cyclin-Dependent Kinases by P21.

Why minimal is not optimal: Driving the mammalian cell cycle—and drug discovery—with a physiologic CDK control network

Cyclin D- and E-Dependent Kinases and the P57(Kip2) Inhibitor: Cooperative Interactions in Vivo

Abstract 872: Deciphering the Activation Mechanism of CDK4/cyclin-D Complex That Differs from the CDK2/cyclin-E Complex

Identification of Human and Mouse P19, a Novel CDK4 and CDK6 Inhibitor with Homology to P16ink4

CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets

Revised view of anticancer drug mechanism

Involvement of CUL4 ubiquitin E3 ligases in regulating CDK inhibitors Dacapo/p27(Kip1) and cyclin E degradation